BCG treatment of superficial transitional cell carcinoma.
Schellhammer
P F
PF
Department of Urology, Eastern Virginia Medical School, Norfolk.
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D015996:Survival Rate; D014523:Urethral Neoplasms / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*
D001500:BCG Vaccine